`Stephen B. Kahl, Ph.D.Stephen B. Kahl, Ph.D.
`
`April 07, 2016April 07, 2016
`
`·
`
`·1· · · ·IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
`
`·2· · · · · ·BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`·3· _________________________________
`· · · · · · · · · · · · · · · · · · ·)
`·4· COALITION FOR AFFORDABLE DRUGS· ·)
`· · X LLC,,· · · · · · · · · · · · · )
`·5· · · · · · · · · · · · · · · · · ·)
`· · · · · · · · · ·Petitioner,· · · ·)
`·6· · · · · · · · · · · · · · · · · ·)
`· · vs.· · · · · · · · · · · · · · · )· No. IPR2015-01776
`·7· · · · · · · · · · · · · · · · · ·)· · · IPR2015-01780
`· · · · · · · · · · · · · · · · · · ·)· · · IPR2015-01785
`·8· ANACOR PHARMACEUTICALS, INC.,· · )
`· · · · · · · · · · · · · · · · · · ·)
`·9· · · · · · · · ·Patent Owner.· · ·)
`· · _________________________________)
`10
`
`11
`
`12· · · · · · · · · · · · · ·VOLUME I
`
`13· · · · · · ·DEPOSITION OF STEPHEN B. KAHL, Ph.D.
`
`14· · · · · · · · · ·San Francisco, California
`
`15· · · · · · · · · · Thursday, April 7, 2016
`
`16· · ·IN RE PATENT NOS. 7,582,621; 7,767,657; and 7,767,657
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24· Reported by:· LANA L. LOPER, RMR, CRR, CCP,
`· · · · · · · · · CME, CLR, CSR No. 9667
`25
`
`
`U.S. LEGAL SUPPORTU.S. LEGAL SUPPORT
`
`(415) 362-4346(415) 362-4346
`
`Page 1
`
`Anacor Exhibit 2010
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00170
`
`
`
`
`Stephen B. Kahl, Ph.D.Stephen B. Kahl, Ph.D.
`
`April 07, 2016April 07, 2016
`
`2
`
`·1· · · ·IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
`
`·2· · · · · ·BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`·3· _________________________________
`· · · · · · · · · · · · · · · · · · ·)
`·4· COALITION FOR AFFORDABLE DRUGS· ·)
`· · X LLC,,· · · · · · · · · · · · · )
`·5· · · · · · · · ·Petitioner,· · · ·)
`· · · · · · · · · · · · · · · · · · ·)
`·6· vs.· · · · · · · · · · · · · · · )· No. IPR2015-01776
`· · · · · · · · · · · · · · · · · · ·)· · · IPR2015-01780
`·7· · · · · · · · · · · · · · · · · ·)· · · IPR2015-01785
`· · ANACOR PHARMACEUTICALS, INC.,· · )
`·8· · · · · · · · · · · · · · · · · ·)
`· · · · · · · · · ·Patent Owner.· · ·)
`·9· _________________________________)
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18· · · · · · Deposition of STEPHEN B. KAHL, Ph.D., taken on
`
`19· behalf of Patent Owner, at One Front Street, 35th Floor,
`
`20· San Francisco, California beginning at 8:49 a.m. and
`
`21· ending at 4:48 p.m., on Thursday, April 7, 2016, before
`
`22· Lana L. Loper, RMR, CRR, CCP, CME, CLR, CSR No. 9667.
`
`23
`
`24
`
`25
`
`
`U.S. LEGAL SUPPORTU.S. LEGAL SUPPORT
`
`(415) 362-4346(415) 362-4346
`
`CFAD v. Anacor, IPR2015-01776
`ANACOR EX. 2033 - 2/583
`
`Page 2
`
`Anacor Exhibit 2010
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00170
`
`
`
`
`Stephen B. Kahl, Ph.D.Stephen B. Kahl, Ph.D.
`
`April 07, 2016April 07, 2016
`
`3
`
`·1· APPEARANCE OF COUNSEL:
`
`·2· FOR THE PETITIONER:
`
`·3· · · ·MERCHANT & GOULD
`
`·4· · · ·BY:· PETER A. GERGELY, ESQ.
`
`·5· · · · · · RYAN JAMES FLETCHER, ESQ.
`
`·6· · · · · · KATHLEEN OTT, ESQ.
`
`·7· · · ·1801 California Street
`
`·8· · · ·Suite 3300
`
`·9· · · ·Denver, Colorado 80202-2654
`
`10· · · ·303-357-1670
`
`11· · · ·pgergely@merchantgould.com
`
`12· · · ·rfletcher@merchantgould.com
`
`13· · · ·kott@merchantgould.com
`
`14· FOR THE PATENT OWNER:
`
`15· · · ·COVINGTON BURLING LLP
`
`16· · · ·BY:· PAUL J. BERMAN, ESQ.
`
`17· · · · · · EVAN KRYGOWSKI, ESQ.
`
`18· · · · · · CHRISTOPHER EPPICH, ESQ. (Los Angeles)
`
`19· · · ·One CityCenter
`
`20· · · ·850 Tenth Street, NW
`
`21· · · ·Washington, DC 20001-4956
`
`22· · · ·202-662-6000
`
`23· · · ·pberman@cov.com
`
`24· · · ·ekrygowski@cov.com
`
`25· · · ·ceppich@cov.com
`
`
`U.S. LEGAL SUPPORTU.S. LEGAL SUPPORT
`
`(415) 362-4346(415) 362-4346
`
`CFAD v. Anacor, IPR2015-01776
`ANACOR EX. 2033 - 3/583
`
`Page 3
`
`Anacor Exhibit 2010
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00170
`
`
`
`
`Stephen B. Kahl, Ph.D.Stephen B. Kahl, Ph.D.
`
`April 07, 2016April 07, 2016
`
`4
`
`·1· · · · · · · · · · · · I N D E X
`
`·2
`
`·3· WITNESS· · · · · · · · · · · · · · · · EXAMINATION
`
`·4· STEPHEN B. KAHL, Ph.D.
`
`·5· · · · · · · · ·BY MR. BERMAN· · · · · · · · 13
`
`·6
`
`·7
`
`·8
`
`·9
`
`10
`
`11
`
`12
`
`13
`
`14· QUESTIONS WITNESS INSTRUCTED NOT TO ANSWER:
`
`15· · · · · · NONE
`
`16
`
`17· INFORMATION TO BE SUPPLIED:
`
`18· · · · · · NONE
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`
`U.S. LEGAL SUPPORTU.S. LEGAL SUPPORT
`
`(415) 362-4346(415) 362-4346
`
`CFAD v. Anacor, IPR2015-01776
`ANACOR EX. 2033 - 4/583
`
`Page 4
`
`Anacor Exhibit 2010
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00170
`
`
`
`
`Stephen B. Kahl, Ph.D.Stephen B. Kahl, Ph.D.
`
`April 07, 2016April 07, 2016
`
`5
`
`·1· · · · · · · · · · · · E X H I B I T S
`
`·2· · · ·COALITION FOR AFFORDABLE DRUGS X LLC, vs. ANACOR
`
`·3· · · · · · · · · · ·PHARMACEUTICALS, INC.
`
`·4· · · · · · · · · · STEPHEN B. KAHL, Ph.D.
`
`·5· · · · · · · · · · · · ·April 7, 2016
`
`·6· EXHIBIT· · · · · · · · · · · · · · · · · ·PAGE
`
`·7· Exhibit 1· · · Patent Owner Anacor· · · · · 15
`
`·8· · · · · · · · ·Pharmaceuticals, Inc.'s
`
`·9· · · · · · · · ·Notice of Deposition of
`
`10· · · · · · · · ·Stephen B. Kahl, Ph.D. in
`
`11· · · · · · · · ·re Case No. IPR2015-01776
`
`12· Exhibit 2· · · Patent Owner Anacor· · · · · 16
`
`13· · · · · · · · ·Pharmaceuticals, Inc.'s
`
`14· · · · · · · · ·Notice of Deposition of
`
`15· · · · · · · · ·Stephen B. Kahl, Ph.D. in
`
`16· · · · · · · · ·re Case No. IPR2015-01780
`
`17· Exhibit 3· · · Patent Owner Anacor· · · · · 16
`
`18· · · · · · · · ·Pharmaceuticals, Inc.'s
`
`19· · · · · · · · ·Notice of Deposition of
`
`20· · · · · · · · ·Stephen B. Kahl, Ph.D. in
`
`21· · · · · · · · ·re Case No. IPR2015-01785
`
`22
`
`23
`
`24
`
`25
`
`
`U.S. LEGAL SUPPORTU.S. LEGAL SUPPORT
`
`(415) 362-4346(415) 362-4346
`
`CFAD v. Anacor, IPR2015-01776
`ANACOR EX. 2033 - 5/583
`
`Page 5
`
`Anacor Exhibit 2010
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00170
`
`
`
`
`Stephen B. Kahl, Ph.D.Stephen B. Kahl, Ph.D.
`
`April 07, 2016April 07, 2016
`
`6
`
`·1· · · · · · · · · · · · E X H I B I T S
`
`·2· · · ·COALITION FOR AFFORDABLE DRUGS X LLC, vs. ANACOR
`
`·3· · · · · · · · · · ·PHARMACEUTICALS, INC.
`
`·4· · · · · · · · · · STEPHEN B. KAHL, Ph.D.
`
`·5· · · · · · · · · · · · ·April 7, 2016
`
`·6· EXHIBIT· · · · · · · · · · · · · · · · · ·PAGE
`
`·7· Exhibit 1006· ·Declaration of Stephen· · · ·25
`
`·8· · · · · · · · ·Kahl, Ph.D. in Support of
`
`·9· · · · · · · · ·Petition for Inter Partes
`
`10· · · · · · · · ·Review of Patent No.
`
`11· · · · · · · · ·7,582,621
`
`12· Exhibit 1009-1 Declaration of Stephen· · · ·32
`
`13· · · · · · · · ·Kahl, Ph.D. in Supportof
`
`14· · · · · · · · ·First Petition for Inter
`
`15· · · · · · · · ·Partes Review of Patent
`
`16· · · · · · · · ·No. 7,767,657
`
`17· Exhibit 1009-2 Declaration of Stephen· · · ·33
`
`18· · · · · · · · ·Kahl, Ph.D., in Support of
`
`19· · · · · · · · ·Second Petition for Inter
`
`20· · · · · · · · ·Partes Review of Patent
`
`21· · · · · · · · ·No. 7,767,657
`
`22· Exhibit 1007· ·University of California· · ·56
`
`23· · · · · · · · ·San Francisco Curriculum
`
`24· · · · · · · · ·Vitae Stephen B. Kahl
`
`25
`
`
`U.S. LEGAL SUPPORTU.S. LEGAL SUPPORT
`
`(415) 362-4346(415) 362-4346
`
`CFAD v. Anacor, IPR2015-01776
`ANACOR EX. 2033 - 6/583
`
`Page 6
`
`Anacor Exhibit 2010
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00170
`
`
`
`Stephen B. Kahl, Ph.D.
`Stephen B. Kahl, Ph.D.
`April 07, 2016
`April 07, 2016
`
`7
`
`·1· · · · · · · · · · · · E X H I B I T S
`
`·2· · · ·COALITION FOR AFFORDABLE DRUGS X LLC, vs. ANACOR
`
`·3· · · · · · · · · · ·PHARMACEUTICALS, INC.
`
`·4· · · · · · · · · · STEPHEN B. KAHL, Ph.D.
`
`·5· · · · · · · · · · · · ·April 7, 2016
`
`·6· EXHIBIT· · · · · · · · · · · · · · · · · ·PAGE
`
`·7· Exhibit 4· · · Handwritten notes re· · · · ·60
`
`·8· · · · · · · · ·Austin
`
`·9· Exhibit 5· · · Handwritten notes re· · · · ·61
`
`10· · · · · · · · ·Brehove
`
`11· Exhibit 6· · · Handwritten notes re· · · · ·62
`
`12· · · · · · · · ·Freeman
`
`13· Exhibit 7· · · Handwritten notes re· · · · ·63
`
`14· · · · · · · · ·Patent Owner Exhibits
`
`15· Exhibit 8· · · Handwritten notes re· · · · ·64
`
`16· · · · · · · · ·Kerydin
`
`17· Exhibit 9· · · Handwritten notes re· · · · ·64
`
`18· · · · · · · · ·Groziak
`
`19· Exhibit 10· · ·United States Patent· · · · ·66
`
`20· · · · · · · · ·Application Publication,
`
`21· · · · · · · · ·US 2002/0165121 A1
`
`22
`
`23
`
`24
`
`25
`
`U.S. LEGAL SUPPORT
`U.S. LEGAL SUPPORT
`(415) 362-4346
`(415) 362-4346
`
`Page 7
`
`Anacor Exhibit 2010
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00170
`
`
`
`
`Stephen B. Kahl, Ph.D.Stephen B. Kahl, Ph.D.
`
`April 07, 2016April 07, 2016
`
`8
`
`·1· · · · · · · · · · · · E X H I B I T S
`
`·2· · · ·COALITION FOR AFFORDABLE DRUGS X LLC, vs. ANACOR
`
`·3· · · · · · · · · · ·PHARMACEUTICALS, INC.
`
`·4· · · · · · · · · · STEPHEN B. KAHL, Ph.D.
`
`·5· · · · · · · · · · · · ·April 7, 2016
`
`·6· EXHIBIT· · · · · · · · · · · · · · · · · ·PAGE
`
`·7· Exhibit 11· · ·Declaration of Stephen· · · ·70
`
`·8· · · · · · · · ·Kahl, Ph.D. in Support of
`
`·9· · · · · · · · ·Petition for Inter Partes
`
`10· · · · · · · · ·Review of Patent No.
`
`11· · · · · · · · ·7,582,621
`
`12· Exhibit 12· · ·International Application· · 71
`
`13· · · · · · · · ·Published Under the Patent
`
`14· · · · · · · · ·Cooperation Treaty (PCT)
`
`15· · · · · · · · ·WO 95/33754 (Austin)
`
`16· Exhibit 13· · ·International Application· · 72
`
`17· · · · · · · · ·Published Under the Patent
`
`18· · · · · · · · ·Cooperation Treaty (PCT)
`
`19· · · · · · · · ·WO 03/009689 A1 (Freeman)
`
`20· Exhibit 14· · ·American Journal of· · · · · 74
`
`21· · · · · · · · ·Therapeutics 8, 321-328
`
`22· · · · · · · · ·(2001) Boron Therapeutics
`
`23· · · · · · · · ·on the Horizon by Michael
`
`24· · · · · · · · ·P. Groziak
`
`25
`
`
`U.S. LEGAL SUPPORTU.S. LEGAL SUPPORT
`
`(415) 362-4346(415) 362-4346
`
`CFAD v. Anacor, IPR2015-01776
`ANACOR EX. 2033 - 8/583
`
`Page 8
`
`Anacor Exhibit 2010
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00170
`
`
`
`
`Stephen B. Kahl, Ph.D.Stephen B. Kahl, Ph.D.
`
`April 07, 2016April 07, 2016
`
`9
`
`·1· · · · · · · · · · · · E X H I B I T S
`
`·2· · · ·COALITION FOR AFFORDABLE DRUGS X LLC, vs. ANACOR
`
`·3· · · · · · · · · · ·PHARMACEUTICALS, INC.
`
`·4· · · · · · · · · · STEPHEN B. KAHL, Ph.D.
`
`·5· · · · · · · · · · · · ·April 7, 2016
`
`·6· EXHIBIT· · · · · · · · · · · · · · · · · ·PAGE
`
`·7· Exhibit 15· · ·Chemical structural· · · · · 79
`
`·8· · · · · · · · ·diagram
`
`·9· Exhibit 16· · ·Chemical structural· · · · · 87
`
`10· · · · · · · · ·diagram
`
`11· Exhibit 17· · ·Chemical structural· · · · · 90
`
`12· · · · · · · · ·diagram
`
`13· Exhibit 18· · ·Chemical structural· · · · · 93
`
`14· · · · · · · · ·diagram
`
`15· Exhibit 19· · ·Chemical structural· · · · ·102
`
`16· · · · · · · · ·diagram
`
`17· Exhibit 20· · ·Chemical structural· · · · ·104
`
`18· · · · · · · · ·diagram
`
`19· Exhibit 21· · ·Chemical structural· · · · ·110
`
`20· · · · · · · · ·diagram
`
`21· Exhibit 22· · ·Chemical structural· · · · ·121
`
`22· · · · · · · · ·diagram
`
`23· Exhibit 23· · ·Chemical structural· · · · ·127
`
`24· · · · · · · · ·diagram
`
`25
`
`
`U.S. LEGAL SUPPORTU.S. LEGAL SUPPORT
`
`(415) 362-4346(415) 362-4346
`
`Page 9
`
`Anacor Exhibit 2010
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00170
`
`
`
`
`Stephen B. Kahl, Ph.D.Stephen B. Kahl, Ph.D.
`
`April 07, 2016April 07, 2016
`
`10
`
`·1· · · · · · · · · · · · E X H I B I T S
`
`·2· · · ·COALITION FOR AFFORDABLE DRUGS X LLC, vs. ANACOR
`
`·3· · · · · · · · · · ·PHARMACEUTICALS, INC.
`
`·4· · · · · · · · · · STEPHEN B. KAHL, Ph.D.
`
`·5· · · · · · · · · · · · ·April 7, 2016
`
`·6· EXHIBIT· · · · · · · · · · · · · · · · · ·PAGE
`
`·7· Exhibit 24· · ·Chemical structural· · · · ·137
`
`·8· · · · · · · · ·diagram
`
`·9· Exhibit 25· · ·Chemical structural· · · · ·139
`
`10· · · · · · · · ·diagram
`
`11· Exhibit 26· · ·Chemical structural· · · · ·142
`
`12· · · · · · · · ·diagram
`
`13· Exhibit 27· · ·Chemical structural· · · · ·144
`
`14· · · · · · · · ·diagram
`
`15· Exhibit 28· · ·Chemical structural· · · · ·147
`
`16· · · · · · · · ·diagram
`
`17· Exhibit 29· · ·Chemical structural· · · · ·149
`
`18· · · · · · · · ·diagram
`
`19· Exhibit 30· · ·Chemical structural· · · · ·162
`
`20· · · · · · · · ·diagram
`
`21· Exhibit 31· · ·Chemical structural· · · · ·166
`
`22· · · · · · · · ·diagram
`
`23· Exhibit 32· · ·Chemical structural· · · · ·171
`
`24· · · · · · · · ·diagram
`
`25
`
`
`U.S. LEGAL SUPPORTU.S. LEGAL SUPPORT
`
`(415) 362-4346(415) 362-4346
`
`CFAD v. Anacor, IPR2015-01776
`ANACOR EX. 2033 - 10/583
`
`Page 10
`
`Anacor Exhibit 2010
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00170
`
`
`
`
`Stephen B. Kahl, Ph.D.Stephen B. Kahl, Ph.D.
`
`April 07, 2016April 07, 2016
`
`11
`
`·1· · · · · · · · · · · · E X H I B I T S
`
`·2· · · ·COALITION FOR AFFORDABLE DRUGS X LLC, vs. ANACOR
`
`·3· · · · · · · · · · ·PHARMACEUTICALS, INC.
`
`·4· · · · · · · · · · STEPHEN B. KAHL, Ph.D.
`
`·5· · · · · · · · · · · · ·April 7, 2016
`
`·6· EXHIBIT· · · · · · · · · · · · · · · · · ·PAGE
`
`·7· Exhibit 33· · ·Chemical structural· · · · ·173
`
`·8· · · · · · · · ·diagram
`
`·9· Exhibit 34· · ·Chemical structural· · · · ·177
`
`10· · · · · · · · ·diagram
`
`11· Exhibit 35· · ·Chemical structural· · · · ·179
`
`12· · · · · · · · ·diagram
`
`13· Exhibit 36· · ·Chemical structural· · · · ·185
`
`14· · · · · · · · ·diagram
`
`15· Exhibit 37· · ·Chemical structural· · · · ·192
`
`16· · · · · · · · ·diagram
`
`17· Exhibit 38· · ·Chemical structural· · · · ·201
`
`18· · · · · · · · ·diagram
`
`19· Exhibit 39· · ·Chemical structural· · · · ·204
`
`20· · · · · · · · ·diagram
`
`21· Exhibit 40· · ·Chemical structural· · · · ·208
`
`22· · · · · · · · ·diagram
`
`23· Exhibit 41· · ·Chemical structural· · · · ·213
`
`24· · · · · · · · ·diagram
`
`25
`
`
`U.S. LEGAL SUPPORTU.S. LEGAL SUPPORT
`
`(415) 362-4346(415) 362-4346
`
`CFAD v. Anacor, IPR2015-01776
`ANACOR EX. 2033 - 11/583
`
`Page 11
`
`Anacor Exhibit 2010
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00170
`
`
`
`
`Stephen B. Kahl, Ph.D.Stephen B. Kahl, Ph.D.
`
`April 07, 2016April 07, 2016
`
`12
`
`·1· · · · · · · · · · · · E X H I B I T S
`
`·2· · · ·COALITION FOR AFFORDABLE DRUGS X LLC, vs. ANACOR
`
`·3· · · · · · · · · · ·PHARMACEUTICALS, INC.
`
`·4· · · · · · · · · · STEPHEN B. KAHL, Ph.D.
`
`·5· · · · · · · · · · · · ·April 7, 2016
`
`·6· EXHIBIT· · · · · · · · · · · · · · · · · ·PAGE
`
`·7· Exhibit 42· · ·Chemical structural· · · · ·214
`
`·8· · · · · · · · ·diagram
`
`·9· Exhibit 43· · ·Chemical structural· · · · ·218
`
`10· · · · · · · · ·diagram
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`
`U.S. LEGAL SUPPORTU.S. LEGAL SUPPORT
`
`(415) 362-4346(415) 362-4346
`
`Page 12
`
`Anacor Exhibit 2010
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00170
`
`
`
`
`Stephen B. Kahl, Ph.D.Stephen B. Kahl, Ph.D.
`
`April 07, 2016April 07, 2016
`
`13
`
`·1· · · San Francisco, California; Thursday, April 7, 2016
`
`·2· · · · · · · · · · ·8:49 a.m. - 4:48 p.m.
`
`·3· · · · · · · · · · · · · · ·- - -
`
`·4· · · · · · · · · · STEPHEN B. KAHL, Ph.D.,
`
`·5· · · · · ·having been first administered an oath
`
`·6· · · · · ·in accordance with CCP Section 2094, was
`
`·7· · · · · ·examined and testified as follows:
`
`·8· · · · · · · · · · · · · EXAMINATION
`
`·9· BY MR. BERMAN:
`
`10· · · ·Q· ·Prof. Kahl, thank you very much for being here
`
`11· today.
`
`12· · · ·A· ·Thank you.
`
`13· · · ·Q· ·My name is Paul Berman.· I'm counsel for Anacor
`
`14· Pharmaceuticals.
`
`15· · · · · ·Can you please state your name for the record?
`
`16· · · ·A· ·My name is Stephen Bruce Kahl.
`
`17· · · ·Q· ·And could you please state your address and
`
`18· occupation also, for the record?
`
`19· · · ·A· ·My home address is One Lerida Court, in Portola
`
`20· Valley, California 94028.
`
`21· · · · · ·And I'm a professor of pharmaceutical chemistry
`
`22· at the University of California in San Francisco.
`
`23· · · ·Q· ·Prof. Kahl, is there any reason why you cannot
`
`24· testify truthfully today?
`
`25· · · ·A· ·No.
`
`
`U.S. LEGAL SUPPORTU.S. LEGAL SUPPORT
`
`(415) 362-4346(415) 362-4346
`
`CFAD v. Anacor, IPR2015-01776
`ANACOR EX. 2033 - 13/583
`
`YVer1f
`
`Page 13
`
`Anacor Exhibit 2010
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00170
`
`
`
`
`Stephen B. Kahl, Ph.D.Stephen B. Kahl, Ph.D.
`
`April 07, 2016April 07, 2016
`
`14
`
`·1· · · ·Q· ·You're not on any medication that makes it hard
`
`·2· to remember things or anything like that?
`
`·3· · · ·A· ·No.
`
`·4· · · ·Q· ·Okay.· Prof. Kahl, have you ever had your
`
`·5· deposition taken before?
`
`·6· · · ·A· ·Yes.
`
`·7· · · ·Q· ·When was that?
`
`·8· · · ·A· ·In 1989.
`
`·9· · · ·Q· ·Okay.· Let me review briefly the ground rules
`
`10· for depositions.
`
`11· · · · · ·I get to ask questions and you get to answer
`
`12· them.
`
`13· · · · · ·If your counsel objects to the question, some
`
`14· legal or other problem, unless it's an objection
`
`15· pertaining to privilege, attorney-client privilege, you
`
`16· need to answer the question.
`
`17· · · · · ·If it's a privileged question, let me know or
`
`18· your counsel will let me know, and we can talk about
`
`19· consulting to resolve the privilege question before you
`
`20· give the answer.· But that's the exception to the rule,
`
`21· which is that when I ask a question, you answer it.
`
`22· Okay?
`
`23· · · · · ·If you need to take a break, let me know.· We'll
`
`24· try and take a break at the next available moment we can.
`
`25· · · ·A· ·Sure.
`
`
`U.S. LEGAL SUPPORTU.S. LEGAL SUPPORT
`
`(415) 362-4346(415) 362-4346
`
`CFAD v. Anacor, IPR2015-01776
`ANACOR EX. 2033 - 14/583
`
`YVer1f
`
`Page 14
`
`Anacor Exhibit 2010
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00170
`
`
`
`
`Stephen B. Kahl, Ph.D.Stephen B. Kahl, Ph.D.
`
`April 07, 2016April 07, 2016
`
`15
`
`·1· · · ·Q· ·And have you ever testified at trial before?
`
`·2· · · ·A· ·No.
`
`·3· · · ·Q· ·Since that deposition in 1987, have you had your
`
`·4· deposition taken since then, or was it 1989?
`
`·5· · · ·A· ·1989.
`
`·6· · · ·Q· ·I beg your pardon.
`
`·7· · · ·A· ·I have not since then.
`
`·8· · · ·Q· ·I'm asking the reporter to mark for
`
`·9· identification as Kahl Deposition 1 a copy of a patent
`
`10· owner -- Anacor Pharmaceuticals, Inc., notice of
`
`11· deposition of Stephen B. Kahl, Ph.D.
`
`12· · · · · ·MR. GERGELY:· After he identifies the exhibit,
`
`13· she'll mark it and hand it to you.· This is the official
`
`14· copy for you to look at.
`
`15· · · ·A· ·Okay.
`
`16· · · · · ·(Patent Owners' Exhibit 1 was marked for
`
`17· · · · · ·identification.)
`
`18· BY MR. BERMAN:
`
`19· · · ·Q· ·Dr. Kahl, have you ever seen this document
`
`20· before?
`
`21· · · ·A· ·This document?
`
`22· · · ·Q· ·Yes.
`
`23· · · ·A· ·No, not to my knowledge.
`
`24· · · ·Q· ·All right.· I'm asking the reporter to mark as
`
`25· Kahl Deposition Exhibit No. 2 a copy of patent owner
`
`
`U.S. LEGAL SUPPORTU.S. LEGAL SUPPORT
`
`(415) 362-4346(415) 362-4346
`
`CFAD v. Anacor, IPR2015-01776
`ANACOR EX. 2033 - 15/583
`
`YVer1f
`
`Page 15
`
`Anacor Exhibit 2010
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00170
`
`
`
`
`Stephen B. Kahl, Ph.D.Stephen B. Kahl, Ph.D.
`
`April 07, 2016April 07, 2016
`
`16
`
`·1· Anacor Pharmaceuticals, Inc., notice of deposition of
`
`·2· Stephen B. Kahl in patent -- in IPR 2015-01780.
`
`·3· · · · · ·(Patent Owners' Exhibit 2 was marked for
`
`·4· · · · · ·identification.)
`
`·5· BY MR. BERMAN:
`
`·6· · · ·Q· ·Have you ever seen this document before --
`
`·7· · · ·A· ·No, I do not believe that I have.
`
`·8· · · ·Q· ·And I'm asking the reporter to mark as Kahl
`
`·9· Exhibit -- Deposition Exhibit No. 3 a copy of patent --
`
`10· Anacor Pharmaceuticals' Notice of Deposition of Stephen
`
`11· B. Kahl, Ph.D, in IPR2015-01785.
`
`12· · · · · ·(Patent Owners' Exhibit 3 was marked for
`
`13· · · · · ·identification.)
`
`14· BY MR. BERMAN:
`
`15· · · ·Q· ·Dr. Kahl, have you ever seen that document
`
`16· before?
`
`17· · · ·A· ·No, I don't believe I have.
`
`18· · · ·Q· ·Dr. Kahl, how did you come to know that you
`
`19· needed to be here for deposition today?
`
`20· · · ·A· ·I was informed by counsel that I had needed to
`
`21· be here today.
`
`22· · · ·Q· ·Which counsel, in particular?
`
`23· · · ·A· ·These gentlemen sitting to my right, and lady.
`
`24· · · ·Q· ·Which -- do you remember who of the three in
`
`25· particular made that call or sent you an e-mail?
`
`
`U.S. LEGAL SUPPORTU.S. LEGAL SUPPORT
`
`(415) 362-4346(415) 362-4346
`
`Page 16
`
`Anacor Exhibit 2010
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00170
`
`
`
`
`Stephen B. Kahl, Ph.D.Stephen B. Kahl, Ph.D.
`
`April 07, 2016April 07, 2016
`
`17
`
`·1· · · ·A· ·I believe it was Ryan Fletcher.
`
`·2· · · ·Q· ·Okay.· Are you represented by counsel here
`
`·3· today?
`
`·4· · · ·A· ·No.
`
`·5· · · ·Q· ·No.
`
`·6· · · · · ·So you don't have an engagement letter with
`
`·7· Merchant & Gould or any of these individuals?
`
`·8· · · · · ·MR. GERGELY:· I mean, he's our expert.· And
`
`·9· we're representing him in connection with the deposition,
`
`10· but like --
`
`11· BY MR. BERMAN:
`
`12· · · ·Q· ·Do you have an engagement letter?
`
`13· · · · · ·MR. GERGELY:· -- like a formal attorney-client
`
`14· thing?
`
`15· · · · · ·MR. BERMAN:· If you have an objection, state,
`
`16· objection.
`
`17· · · · · ·If he's got a problem understanding the
`
`18· question, he can tell me.
`
`19· BY MR. BERMAN:
`
`20· · · ·Q· ·Do you have an engagement letter with Merchant &
`
`21· Gould?
`
`22· · · ·A· ·Yes.
`
`23· · · ·Q· ·Are they acting as your counsel today?
`
`24· · · ·A· ·I believe that's the case, yes.
`
`25· · · ·Q· ·Does your engagement letter specify that you are
`
`
`U.S. LEGAL SUPPORTU.S. LEGAL SUPPORT
`
`(415) 362-4346(415) 362-4346
`
`CFAD v. Anacor, IPR2015-01776
`ANACOR EX. 2033 - 17/583
`
`YVer1f
`
`Page 17
`
`Anacor Exhibit 2010
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00170
`
`
`
`
`Stephen B. Kahl, Ph.D.Stephen B. Kahl, Ph.D.
`
`April 07, 2016April 07, 2016
`
`18
`
`·1· retaining them as counsel?
`
`·2· · · ·A· ·I honestly have not looked at the engagement
`
`·3· letter.· I cannot say.· They have re --
`
`·4· · · ·Q· ·Do you want to complete that sentence?
`
`·5· · · ·A· ·They have retained me to advise them on these
`
`·6· matters.
`
`·7· · · ·Q· ·Okay.· They have retained you, not you retained
`
`·8· them, correct?
`
`·9· · · ·A· ·Correct.
`
`10· · · ·Q· ·Have you ever testified at trial?
`
`11· · · ·A· ·No.
`
`12· · · ·Q· ·And how did you prepare for this deposition?
`
`13· · · ·A· ·I reread my declaration.
`
`14· · · · · ·I read the various patents and documents
`
`15· involved in the case.
`
`16· · · ·Q· ·You have three declarations in these three
`
`17· proceedings, correct?
`
`18· · · ·A· ·Correct.
`
`19· · · ·Q· ·Did you read one, two, or three of them in
`
`20· preparation for this deposition?
`
`21· · · ·A· ·I read one.
`
`22· · · ·Q· ·Which one?
`
`23· · · ·A· ·Inter partes review of Patent No. 7,582,621.
`
`24· · · ·Q· ·So you didn't read the other two declarations,
`
`25· one with respect to the '657 patent?
`
`
`U.S. LEGAL SUPPORTU.S. LEGAL SUPPORT
`
`(415) 362-4346(415) 362-4346
`
`CFAD v. Anacor, IPR2015-01776
`ANACOR EX. 2033 - 18/583
`
`YVer1f
`
`Page 18
`
`Anacor Exhibit 2010
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00170
`
`
`
`
`Stephen B. Kahl, Ph.D.Stephen B. Kahl, Ph.D.
`
`April 07, 2016April 07, 2016
`
`19
`
`·1· · · ·A· ·I did not reread them, no.
`
`·2· · · ·Q· ·Dr. Kahl, I notice before you a folder of
`
`·3· documents on yellow.· They appear to be handwriting on
`
`·4· it.· I can't read them --
`
`·5· · · ·A· ·Yes.
`
`·6· · · ·Q· ·-- and others.
`
`·7· · · · · ·You intend to refer to those during this
`
`·8· deposition?
`
`·9· · · ·A· ·I do.
`
`10· · · ·Q· ·I would like to have each one separately marked
`
`11· as an exhibit.
`
`12· · · · · ·We'll copy them during the break.· And we're
`
`13· certainly happy to give them back to you.
`
`14· · · ·A· ·Certainly.
`
`15· · · ·Q· ·I don't know what you have, so if you want to
`
`16· pass them to me, I'll give them to the reporter and we
`
`17· can worry about the content of them later.
`
`18· · · · · ·MR. GERGELY:· Paul, do you mind if I just take a
`
`19· quick glance before he does that?
`
`20· · · · · ·MR. BERMAN:· You can glance at them, but they're
`
`21· all going -- they're going to be exhibits.
`
`22· · · · · ·You can glance at them now or later.
`
`23· · · · · ·THE WITNESS:· What we talked about yesterday.
`
`24· · · · · ·MR. GERGELY:· Just give me a minute.
`
`25· · · · · ·Okay.· Do you want them now?
`
`
`U.S. LEGAL SUPPORTU.S. LEGAL SUPPORT
`
`(415) 362-4346(415) 362-4346
`
`CFAD v. Anacor, IPR2015-01776
`ANACOR EX. 2033 - 19/583
`
`YVer1f
`
`Page 19
`
`Anacor Exhibit 2010
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00170
`
`
`
`
`Stephen B. Kahl, Ph.D.Stephen B. Kahl, Ph.D.
`
`April 07, 2016April 07, 2016
`
`20
`
`·1· · · · · ·MR. BERMAN:· Well, I would like to have them
`
`·2· marked as exhibits now.
`
`·3· · · · · ·We can have them -- we can wait until we make
`
`·4· copies.
`
`·5· · · · · ·MR. GERGELY:· It's up to you, whatever you want.
`
`·6· · · · · ·If you want to take a five-minute break and make
`
`·7· copies --
`
`·8· · · · · ·MR. BERMAN:· Why don't we -- that would be fine.
`
`·9· · · · · ·Thank you.
`
`10· · · · · ·(Discussion off the record.)
`
`11· BY MR. BERMAN:
`
`12· · · ·Q· ·We can go back on.
`
`13· · · · · ·Dr. Kahl, I was -- before we went off the
`
`14· record, I was asking you about documents you reviewed in
`
`15· preparation for this deposition.
`
`16· · · ·A· ·Uh-huh.
`
`17· · · ·Q· ·I would like to be a little more specific.
`
`18· · · · · ·Did you review U.S. Patent No. 7,767,657?
`
`19· · · ·A· ·Can you give me the author of that?
`
`20· · · ·Q· ·It's the patent in the second two -- can you
`
`21· hand me a copy of it?
`
`22· · · · · ·Can we refer to it as the '657 patent?
`
`23· · · · · ·The inventors are Stephen J. Baker, Tsutomu
`
`24· Akama --
`
`25· · · ·A· ·Uh-huh, yes.
`
`
`U.S. LEGAL SUPPORTU.S. LEGAL SUPPORT
`
`(415) 362-4346(415) 362-4346
`
`Page 20
`
`Anacor Exhibit 2010
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00170
`
`
`
`
`Stephen B. Kahl, Ph.D.Stephen B. Kahl, Ph.D.
`
`April 07, 2016April 07, 2016
`
`21
`
`·1· · · ·Q· ·-- and eight or nine other people.
`
`·2· · · · · ·Did you review that patent?
`
`·3· · · ·A· ·I did.
`
`·4· · · ·Q· ·Did you review U.S. Patent No. 7,582,621 by the
`
`·5· same inventors?
`
`·6· · · ·A· ·Yes.
`
`·7· · · ·Q· ·May we refer in this deposition to the 7,767,657
`
`·8· as the '657 patent?
`
`·9· · · ·A· ·Yes.
`
`10· · · ·Q· ·And may we refer to 7,582,621 as the '621
`
`11· patent?
`
`12· · · ·A· ·Yes.
`
`13· · · ·Q· ·Specifically, what other documents did you
`
`14· review in preparation for this deposition?
`
`15· · · ·A· ·You're copying several of them at the moment, so
`
`16· I would have to be able to see the -- I can give you the
`
`17· authors.
`
`18· · · ·Q· ·Okay.
`
`19· · · ·A· ·Groziak.
`
`20· · · ·Q· ·Please.
`
`21· · · · · ·Uh-huh.
`
`22· · · ·A· ·The review by Groziak.
`
`23· · · · · ·The patent of Austin, et al.
`
`24· · · ·Q· ·Uh-huh.
`
`25· · · ·A· ·The patent of Brehove, et al.; the patent of
`
`
`U.S. LEGAL SUPPORTU.S. LEGAL SUPPORT
`
`(415) 362-4346(415) 362-4346
`
`CFAD v. Anacor, IPR2015-01776
`ANACOR EX. 2033 - 21/583
`
`YVer1f
`
`Page 21
`
`Anacor Exhibit 2010
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00170
`
`
`
`
`Stephen B. Kahl, Ph.D.Stephen B. Kahl, Ph.D.
`
`April 07, 2016April 07, 2016
`
`22
`
`·1· Freeman, et al.
`
`·2· · · · · ·Oh, I reviewed all of the documents in the
`
`·3· Anacor response, which in -- and I don't have a list in
`
`·4· front of me, so I can't specifically refer to those.
`
`·5· · · ·Q· ·Uh-huh.
`
`·6· · · · · ·Okay.· Anything else?
`
`·7· · · ·A· ·I think that's an accurate list.
`
`·8· · · ·Q· ·In the proceeding concerning the '621 patent,
`
`·9· did you review any documents that were not identified in
`
`10· your declaration or not identified in Anacor's response?
`
`11· · · ·A· ·Not to my knowledge.
`
`12· · · ·Q· ·In the proceeding concerning the '657 patent --
`
`13· in the proceedings concerning the '657 patent, did you
`
`14· review in preparation for this deposition any documents
`
`15· that were not cited in your declaration or in Anacor's
`
`16· responses?
`
`17· · · ·A· ·Not to my knowledge.
`
`18· · · ·Q· ·Okay.· Did you meet with anybody in preparation
`
`19· for this deposition?
`
`20· · · ·A· ·Yes.
`
`21· · · ·Q· ·Who?
`
`22· · · ·A· ·Mr. Gergely, Mr. Fletcher, Ms. Ott.
`
`23· · · ·Q· ·Was there one meeting or more than one meeting?
`
`24· · · ·A· ·There was more than one meeting.
`
`25· · · ·Q· ·And when were those meetings?
`
`
`U.S. LEGAL SUPPORTU.S. LEGAL SUPPORT
`
`(415) 362-4346(415) 362-4346
`
`CFAD v. Anacor, IPR2015-01776
`ANACOR EX. 2033 - 22/583
`
`YVer1f
`
`Page 22
`
`Anacor Exhibit 2010
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00170
`
`
`
`
`Stephen B. Kahl, Ph.D.Stephen B. Kahl, Ph.D.
`
`April 07, 2016April 07, 2016
`
`23
`
`·1· · · ·A· ·Yesterday, the 6th of April; last Thursday,
`
`·2· which would have been -- whatever day that was.
`
`·3· · · ·Q· ·March 31?
`
`·4· · · ·A· ·Yes.
`
`·5· · · · · ·And, I believe, last Wednesday, March 30th.
`
`·6· · · ·Q· ·How long was the meeting on March 30th?
`
`·7· · · ·A· ·March 30th was Wednesday.
`
`·8· · · · · ·It would have been approximately four hours.
`
`·9· · · ·Q· ·And where was that meeting?
`
`10· · · ·A· ·That meeting was in the Pickwick Hotel in
`
`11· San Francisco.
`
`12· · · ·Q· ·And the meeting on March 31st, how long was it?
`
`13· · · ·A· ·Approximately four hours.
`
`14· · · ·Q· ·Where was it?
`
`15· · · ·A· ·In the Pickwick Hotel.
`
`16· · · ·Q· ·And the meeting yesterday, where was it?
`
`17· · · ·A· ·It was in the Harbor Court Hotel.
`
`18· · · ·Q· ·Is that in San Francisco?
`
`19· · · ·A· ·Yes.
`
`20· · · ·Q· ·And how long was that?
`
`21· · · ·A· ·About two and a half hours.
`
`22· · · ·Q· ·Was anybody other than the three of these
`
`23· lawyers present at any of those meetings?
`
`24· · · ·A· ·No.
`
`25· · · ·Q· ·Did you have any conference calls or other
`
`
`U.S. LEGAL SUPPORTU.S. LEGAL SUPPORT
`
`(415) 362-4346(415) 362-4346
`
`Page 23
`
`Anacor Exhibit 2010
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00170
`
`
`
`
`Stephen B. Kahl, Ph.D.Stephen B. Kahl, Ph.D.
`
`April 07, 2016April 07, 2016
`
`24
`
`·1· communications in preparation for this deposition?
`
`·2· · · ·A· ·No.
`
`·3· · · ·Q· ·Did you speak with anybody else in preparation
`
`·4· for this deposition?
`
`·5· · · ·A· ·No.
`
`·6· · · ·Q· ·Did you e-mail or otherwise communicate with
`
`·7· anyone in preparation for this deposition?
`
`·8· · · ·A· ·No.
`
`·9· · · · · ·MR. BERMAN:· I'm asking the reporter to mark as
`
`10· Kahl Deposition Exhibit 1006 a copy of the declaration of
`
`11· Stephen Kahl, Ph.D., in support of petition for
`
`12· inter partes review of patent No. 7,582,621.
`
`13· · · · · ·MR. GERGELY:· So the numbering protocol is, if
`
`14· it's a new document that's not a record, it's going to go
`
`15· 1, 2, 3, but if it's already of record, we're just going
`
`16· to use the original?
`
`17· · · · · ·MR. BERMAN:· Yes, with the exception of Exhibits
`
`18· 1009, which would be 1009-1 and 1009-2.
`
`19· · · · · ·MR. GERGELY:· Okay.
`
`20· · · · · ·MR. BERMAN:· And if they're similar --
`
`21· · · · · ·MR. GERGELY:· Okay.
`
`22· · · · · ·MR. BERMAN:· -- situations.
`
`23· · · · · ·MR. GERGELY:· Okay.· Thanks.
`
`24· · · · · ·THE WITNESS:· They have my copy of this
`
`25· document, so...
`
`
`U.S. LEGAL SUPPORTU.S. LEGAL SUPPORT
`
`(415) 362-4346(415) 362-4346
`
`CFAD v. Anacor, IPR2015-01776
`ANACOR EX. 2033 - 24/583
`
`YVer1f
`
`Page 24
`
`Anacor Exhibit 2010
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00170
`
`
`
`
`Stephen B. Kahl, Ph.D.Stephen B. Kahl, Ph.D.
`
`April 07, 2016April 07, 2016
`
`25
`
`·1· · · · · ·(Patent Owners' Exhibit 1006 was marked
`
`·2· · · · · ·for identification.)
`
`·3· BY MR. BERMAN:
`
`·4· · · ·Q· ·Dr. Kahl, is this your declaration in support of
`
`·5· the petition for inter partes review of Patent No. '621,
`
`·6· patent in IPR2015-01776?
`
`·7· · · ·A· ·It appears to be.
`
`·8· · · ·Q· ·Do you have any corrections or changes that you
`
`·9· would like to make to this declaration?
`
`10· · · ·A· ·No.
`
`11· · · ·Q· ·Would you please turn to paragraph 13 of
`
`12· Exhibit 1006, please?
`
`13· · · ·A· ·Uh-huh.
`
`14· · · ·Q· ·Paragraph 13 states, "I reviewed the following
`
`15· documents and information," and then provides a list,
`
`16· correct?
`
`17· · · ·A· ·Correct.
`
`18· · · ·Q· ·In preparing your declaration, did you review
`
`19· any other documents than those provided in -- than those
`
`20· identified in paragraph 13?
`
`21· · · ·A· ·I don't believe so.
`
`22· · · ·Q· ·So that's, no, you didn't?
`
`23· · · ·A· ·I don't believe that I did.
`
`24· · · ·Q· ·Is there some uncertainty?
`
`25· · · ·A· ·I have a list here that I recognize.
`
`
`U.S. LEGAL SUPPORTU.S. LEGAL SUPPORT
`
`(415) 362-4346(415) 362-4346
`
`CFAD v. Anacor, IPR2015-01776
`ANACOR EX. 2033 - 25/583
`
`YVer1f
`
`Page 25
`
`Anacor Exhibit 2010
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00170
`
`
`
`
`Stephen B. Kahl, Ph.D.Stephen B. Kahl, Ph.D.
`
`April 07, 2016April 07, 2016
`
`26
`
`·1· · · · · ·I'm not aware that there's anything missing from
`
`·2· the list.
`
`·3· · · ·Q· ·And, Dr. Kahl, in preparing this declaratio